TELIX Pharmaceuticals Ltd Capital Reinvestment Ratio
TELIX Pharmaceuticals Ltd capital reinvestment ratio. TELIX Pharmaceuticals Ltd (TLX) has a Capital Reinvestment Ratio of 0.36x as of June 2025, meaning it reinvests 0% of its operating cash flow (AU$27.98 Million) in capital expenditures (AU$10.13 Million). See TELIX Pharmaceuticals Ltd (TLX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of TELIX Pharmaceuticals Ltd (2020–2024)
Capital reinvestment ratio of TELIX Pharmaceuticals Ltd from 2020 to 2024. This chart tracks TELIX Pharmaceuticals Ltd's Capital Reinvestment Ratio across 3 annual periods. See TELIX Pharmaceuticals Ltd (TLX) financial flexibility to measure the company's free cash flow as a share of total liabilities.
TELIX Pharmaceuticals Ltd Capital Reinvestment Ratio by Year (2020–2024)
TELIX Pharmaceuticals Ltd capital reinvestment ratio by year from 2020 to 2024. For the full cash flow conversion analysis, see TLX cash generation efficiency.
| Year | Reinvestment Ratio | Operating CF (AUD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.79x | AU$43.03 Million | AU$34.03 Million | ▲ +75.0% |
| 2023 | 0.45x | AU$23.88 Million | AU$10.79 Million | ▲ +175.1% |
| 2020 | 0.16x | AU$1.96 Million | AU$322.00K | — |